Last reviewed · How we verify
Coly Mycin M Injectable Product
Colistin (polymyxin E) is a cyclic polypeptide antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death.
Colistin (polymyxin E) is a cyclic polypeptide antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides and phospholipids, leading to cell lysis and death. Used for Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii), Serious infections in hospitalized patients unresponsive to other antibiotics.
At a glance
| Generic name | Coly Mycin M Injectable Product |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | Polymyxin antibiotic |
| Target | Bacterial lipopolysaccharides and phospholipids |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Colistin is a last-resort antibiotic primarily used against multidrug-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa and Acinetobacter baumannii. It acts as a cationic surfactant that penetrates and destabilizes the outer and inner membranes of gram-negative bacteria. The injectable formulation (Coly Mycin M) is administered intravenously or intramuscularly for systemic infections.
Approved indications
- Multidrug-resistant gram-negative bacterial infections (Pseudomonas aeruginosa, Acinetobacter baumannii)
- Serious infections in hospitalized patients unresponsive to other antibiotics
Common side effects
- Nephrotoxicity (acute kidney injury)
- Neurotoxicity (paresthesias, dizziness, vertigo)
- Injection site reactions
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: